MPLT
MapLight Therapeutics, Inc.
Price Chart
Latest Quote
$30.13
+1.49 (+5.20%)
Current Price
| Previous Close | $28.64 |
| Open | $28.61 |
| Day High | $30.55 |
| Day Low | $28.18 |
| Volume | 125,475 |
Stock Information
| Shares Outstanding | 42.62M |
| Total Debt | $5.59M |
| Cash Equivalents | $310.11M |
| Net Income | $-199.48M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.37B |
| EPS (TTM) | $-4.41 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $994.18M |
| Income | $-199.48M |
| Book/sh | $8.84 |
| Cash/sh | $7.28 |
| Employees | 133 |
Financial Ratios
| Quick Ratio | 21.71 |
| Current Ratio | 22.91 |
| Debt/Eq | 1.40 |
Returns & Margins
| ROA | -49.50% |
| ROE | -80.95% |
Ownership
| Insider Ownership | 51.16% |
| Institutional Ownership | 55.98% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.93 |
| P/B | 3.41 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $39.20 |
Technical Indicators
| SMA20 | $28.93 |
| SMA50 | $29.04 |
| RSI | 54.67 |
| ATR | 2.5304 |
| Shares Float | 13.40M |
| Short Float | 7.10% |
| Short Ratio | 5.98 |
| Rel Volume | 0.33 |
Performance History
| Week | +10.94% |
| Month | +4.80% |
| Quarter | +77.44% |
| 6 Months | +46.62% |
| YTD | +79.67% |
| 10 Years | +64.29% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $30.13 | 125,475 |
| 2026-06-23 | $28.64 | 360,100 |
| 2026-06-22 | $29.79 | 654,800 |
| 2026-06-18 | $28.82 | 1,466,900 |
| 2026-06-17 | $29.21 | 410,700 |
| 2026-06-16 | $27.16 | 203,100 |
| 2026-06-15 | $27.96 | 205,000 |
| 2026-06-12 | $27.75 | 324,400 |
| 2026-06-11 | $30.35 | 255,500 |
| 2026-06-10 | $27.80 | 184,000 |
| 2026-06-09 | $29.27 | 251,900 |
| 2026-06-08 | $29.46 | 235,100 |
| 2026-06-05 | $28.01 | 478,200 |
| 2026-06-04 | $30.10 | 397,300 |
| 2026-06-03 | $28.34 | 193,400 |
| 2026-06-02 | $27.34 | 467,800 |
| 2026-06-01 | $29.76 | 270,600 |
| 2026-05-29 | $29.31 | 436,900 |
| 2026-05-28 | $29.78 | 485,700 |
| 2026-05-27 | $29.55 | 269,300 |
| 2026-05-26 | $29.46 | 212,000 |
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
đ° Latest News
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Motley Fool âĸ 2026-06-08T11:16:03Z
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Motley Fool âĸ 2026-05-31T14:39:50Z
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
Motley Fool âĸ 2026-05-30T16:48:24Z
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold?
Motley Fool âĸ 2026-05-15T18:43:03Z
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April
Motley Fool âĸ 2026-05-04T15:29:23Z
We're Hopeful That MapLight Therapeutics (NASDAQ:MPLT) Will Use Its Cash Wisely
Simply Wall St. âĸ 2026-04-26T13:37:44Z
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data
Motley Fool âĸ 2026-04-22T18:03:45Z
TD Cowen Initiates on MapLight (MPLT); Says Itâs Undervalued on Schizophrenia Alone
Insider Monkey âĸ 2026-04-20T14:48:27Z
MapLight Therapeutics (MPLT): The Best Healthcare Stock Insiders Are Buying
Insider Monkey âĸ 2026-04-12T21:35:08Z
Sector Update: Health Care Stocks Increase Late Afternoon
MT Newswires âĸ 2025-10-27T19:57:13Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $0 | - | - |
| Operating Revenue | $0 | - | - |
| Expenses | |||
| Total Expenses | $169,083,000 | - | - |
| Other Income Expense | $2,413,000 | - | - |
| Other Non Operating Income Expenses | $2,413,000 | - | $-512,000 |
| Net Non Operating Interest Income Expense | $5,518,000 | - | - |
| Operating Expense | $169,083,000 | - | - |
| General And Administrative Expense | $30,734,000 | - | - |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-161,152,000 | - | - |
| Net Interest Income | $5,518,000 | - | - |
| Interest Income | $5,518,000 | - | - |
| Normalized Income | $-161,152,000 | - | $-55,709,000 |
| Net Income From Continuing And Discontinued Operation | $-161,152,000 | - | - |
| Total Operating Income As Reported | $-169,083,000 | - | - |
| Net Income Common Stockholders | $-161,152,000 | - | - |
| Net Income | $-161,152,000 | - | - |
| Net Income Including Noncontrolling Interests | $-161,152,000 | - | - |
| Net Income Continuous Operations | $-161,152,000 | - | - |
| Pretax Income | $-161,152,000 | - | - |
| Earnings From Equity Interest | $0 | - | - |
| Interest Income Non Operating | $5,518,000 | - | - |
| Operating Income | $-169,083,000 | - | - |
| Per Share | |||
| Diluted EPS | $-18.56 | $-2.96 | - |
| Basic EPS | $-18.56 | $-2.96 | - |
| Other | |||
| Tax Effect Of Unusual Items | $0 | - | - |
| Tax Rate For Calcs | $0 | - | - |
| Normalized EBITDA (Bullshit earnings) | $-168,505,000 | - | $-56,726,000 |
| Reconciled Depreciation | $578,000 | - | - |
| EBITDA (Bullshit earnings) | $-168,505,000 | - | - |
| EBIT | $-169,083,000 | - | - |
| Diluted Average Shares | $8,680,741 | $26,175,299 | - |
| Basic Average Shares | $8,680,741 | $26,175,299 | - |
| Diluted NI Availto Com Stockholders | $-161,152,000 | - | - |
| Research And Development | $138,349,000 | - | - |
| Selling General And Administration | $30,734,000 | - | - |
| Other Gand A | $9,046,000 | - | - |
| Salaries And Wages | $21,688,000 | - | - |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $458,372,000 | $115,195,000 | $71,282,000 | $20,870,000 |
| Total Assets | $479,512,000 | - | - | - |
| Total Non Current Assets | $154,842,000 | - | - | - |
| Other Non Current Assets | $266,000 | - | - | - |
| Investmentin Financial Assets | $147,993,000 | - | - | - |
| Current Assets | $324,670,000 | - | - | - |
| Other Current Assets | $19,567,000 | - | - | - |
| Cash Cash Equivalents And Short Term Investments | $305,103,000 | - | - | - |
| Cash And Cash Equivalents | $46,729,000 | - | - | - |
| Debt | ||||
| Total Debt | $5,802,000 | - | - | - |
| Long Term Debt And Capital Lease Obligation | $4,911,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $891,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $21,140,000 | $21,721,000 | $20,127,000 | $18,519,000 |
| Total Non Current Liabilities Net Minority Interest | $4,911,000 | $5,801,000 | $5,429,000 | $5,923,000 |
| Current Liabilities | $16,229,000 | - | - | - |
| Current Deferred Liabilities | $0 | - | - | - |
| Payables And Accrued Expenses | $9,176,000 | - | - | - |
| Payables | $3,289,000 | - | - | - |
| Accounts Payable | $3,289,000 | - | - | - |
| Equity | ||||
| Common Stock Equity | $458,372,000 | - | - | - |
| Total Equity Gross Minority Interest | $458,372,000 | $115,195,000 | $71,282,000 | $20,870,000 |
| Stockholders Equity | $458,372,000 | $115,195,000 | $71,282,000 | $20,870,000 |
| Gains Losses Not Affecting Retained Earnings | $-228,000 | - | - | - |
| Other Equity Adjustments | $-228,000 | - | - | - |
| Retained Earnings | $-360,520,000 | - | - | - |
| Other | ||||
| Ordinary Shares Number | $44,024,088 | - | - | - |
| Share Issued | $44,024,088 | - | - | - |
| Tangible Book Value | $458,372,000 | - | - | - |
| Invested Capital | $458,372,000 | - | - | - |
| Working Capital | $308,441,000 | - | - | - |
| Capital Lease Obligations | $5,802,000 | - | - | - |
| Total Capitalization | $458,372,000 | $115,195,000 | $71,282,000 | $20,870,000 |
| Additional Paid In Capital | $819,115,000 | - | - | - |
| Capital Stock | $5,000 | $308,823,000 | $188,867,000 | $83,831,000 |
| Common Stock | $5,000 | - | - | - |
| Preferred Stock | $0 | - | - | - |
| Long Term Capital Lease Obligation | $4,911,000 | - | - | - |
| Current Deferred Revenue | $0 | - | - | - |
| Current Capital Lease Obligation | $891,000 | - | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | $6,162,000 | - | - | - |
| Current Accrued Expenses | $5,887,000 | - | - | - |
| Investments And Advances | $147,993,000 | - | - | - |
| Available For Sale Securities | $147,993,000 | $11,380,000 | - | - |
| Net PPE | $6,583,000 | - | - | - |
| Accumulated Depreciation | $-2,639,000 | - | - | - |
| Gross PPE | $9,222,000 | - | - | - |
| Other Properties | $8,595,000 | $9,016,000 | - | - |
| Machinery Furniture Equipment | $627,000 | $627,000 | - | - |
| Other Short Term Investments | $258,374,000 | - | - | - |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Free Cash Flow | |
| Free Cash Flow | $-138,610,000 |
| Operating Activities | |
| Operating Cash Flow | $-138,137,000 |
| Cash Flow From Continuing Operating Activities | $-138,137,000 |
| Operating Gains Losses | $7,000 |
| Investing Activities | |
| Capital Expenditure | $-473,000 |
| Investing Cash Flow | $-323,207,000 |
| Cash Flow From Continuing Investing Activities | $-323,207,000 |
| Financing Activities | |
| Issuance Of Capital Stock | $474,556,000 |
| Financing Cash Flow | $469,820,000 |
| Cash Flow From Continuing Financing Activities | $469,820,000 |
| Net Other Financing Charges | $-5,021,000 |
| Net Preferred Stock Issuance | $474,556,000 |
| Preferred Stock Issuance | $474,556,000 |
| Other | |
| End Cash Position | $46,936,000 |
| Beginning Cash Position | $38,460,000 |
| Changes In Cash | $8,476,000 |
| Proceeds From Stock Option Exercised | $285,000 |
| Net Investment Purchase And Sale | $-322,734,000 |
| Sale Of Investment | $85,500,000 |
| Purchase Of Investment | $-408,234,000 |
| Net PPE Purchase And Sale | $-473,000 |
| Purchase Of PPE | $-473,000 |
| Change In Working Capital | $-12,836,000 |
| Change In Other Working Capital | $-3,239,000 |
| Change In Other Current Liabilities | $-777,000 |
| Change In Payables And Accrued Expense | $4,283,000 |
| Change In Accrued Expense | $2,899,000 |
| Change In Payable | $1,384,000 |
| Change In Account Payable | $1,384,000 |
| Change In Prepaid Assets | $-13,103,000 |
| Other Non Cash Items | $1,362,000 |
| Stock Based Compensation | $36,006,000 |
| Amortization Of Securities | $-2,102,000 |
| Depreciation Amortization Depletion | $578,000 |
| Depreciation And Amortization | $578,000 |
| Depreciation | $578,000 |
| Earnings Losses From Equity Investments | $0 |
| Gain Loss On Sale Of PPE | $7,000 |
| Net Income From Continuing Operations | $-161,152,000 |
Fetched: 2026-06-20